Ezetimibe
Price | USD1.00 |
Packge | 1KG |
- Min. Order:1G
- Supply Ability:100KG
- Time:2019-07-06
Product Details
- Product NameEzetimibe
- CAS No.163222-33-1
- EINECS No.682-606-0
- MFC24H21F2NO3
- MW409.43
- AppearancepowderWhite or off-white
- Melting point 164-166°C
- storage temp. 2-8°C
- Boiling point 654.9±55.0 °C(Predicted)
- density 1.334±0.06 g/cm3(Predicted)
AD68
Ezetimibe Basic information |
Product Name: | Ezetimibe |
Synonyms: | (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one;Ticagrelor and its interMediate;Ezetimibe 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one;Ezatimibe;zetia/vytorin;SCH 60969;Ezetimibe, >=99%;(3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azeti |
CAS: | 163222-33-1 |
MF: | C24H21F2NO3 |
MW: | 409.43 |
EINECS: | 1308068-626-2 |
Product Categories: | Final material;API;Isotope;CEDAX;Cardiovascular APIs;Ezetimibe;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals |
Mol File: | 163222-33-1.mol |
Ezetimibe Chemical Properties |
Melting point | 164-166°C |
alpha | D22 -33.9° (c = 3 in methanol) |
storage temp. | -20?C Freezer |
CAS DataBase Reference | 163222-33-1(CAS DataBase Reference) |
Safety Information |
Risk Statements | 36/37/38 |
Safety Statements | 26-36-24/25 |
Ezetimibe Usage And Synthesis |
Description | Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol. |
Indications and Usage | Ezetimibe is a new form of selective cholesterol absorption inhibitor developed in a collaboration between Schering-Plough Co. and Merck Co. This drug is the first cholesterol absorption selective inhibitor to be approved for sale by the American FDA. Its commercial name is Ezetrol. This drug can be used alone or in combination with HMG-CoA reductase inhibitors (statins) to treat primary (heterozygous familial and non-familial) hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous viremia (or phytosterolemia). |
Mechanisms of Action | Ezetimibe’s mechanisms of action are different from those of other lipid-lowering drugs (such as statins, cholic acid chelating agents, phenoxy acid derivatives, and plant sterols). This drug binds with the surface proteins on the brush border membrane vesicles of the small intestine (relative molecular mass 145x10^3) to inhibit the small intestine’s absorption of cholesterol in food and bile, thus decreasing the cholesterol content in serum and the liver. Ezetimibe is different from bile acid sequestrants because it does not affect the absorption of cholesterol esters, other steroids (such as bezoar and cholic acid), three triacylglycerol, and fat-soluble vitamins. Its effects are unrelated to whether or not acetyl coenzyme A- cholesterol acetyltransferase (ACAT) is inhibited or whether or not the LDL receptor (scavenger receptor) is expressed. After Ezetimibe is absorbed and binds with glucuronic acid in the liver, it undergoes enterohepatic circulation and almost exclusively targets small intestine mucosa cells. |
References | https://en.wikipedia.org/wiki/Ezetimibe https://pubchem.ncbi.nlm.nih.gov/compound/Ezetimibe#section=Top https://www.drugbank.ca/drugs/DB00973 Davidson, Michael H, et al. "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia ☆." Journal of the American College of Cardiology 40.12(2002):2125. Sudhop, T, et al. "Inhibition of intestinal cholesterol absorption by ezetimibe in humans. " Circulation 106.15(2002):1943-8. |
Chemical Properties | White Solid |
Uses | An antihyperlipoproteinemic. A Cholesterol absorption inhibitor |
Uses | antibacterial |
Uses | A cholesterol transport inhibitor that binds to NPC1L1 |
Uses | For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. |
Company Profile Introduction
Henan CoreyChem Co., Ltd, based on the original Zhengzhou Cote Chemical Research Institute, be brave in absorbing highly educated talents & overseas returnees; actively responded to Zhengzhou City High-tech Zone Government’s Special Care Policy, reorganized and founded in National University of Science and Technology Park, which is a high-tech, stock enterprise of high-end chemical Custom synthesis;The park was created by the People's Government of Henan Province, and proved by Ministry of Education and the National Science & Technology, taking the construction mode of "many college a park, and common development", mainly depends on Zhengzhou University and Henan University’s scientific research and talent advantage to set up Universities, scientific research institute and enterprise scientific research achievements transformation platform, to make high-tech enterprises incubate, is the new high-tech talent gathering base, high and new technology industry enterprise radiation base, colleges and universities technological innovation base.
Henan Coreychem Co., Ltd, facing global High-tech pharmaceutical raw materials, high complex new type intermediates, fine chemicals custom synthesis, scale-up production and Rare chemicals trade. Corey have well-equipped machine, strong technical force and considerate marketing team service. We also have rich experience advantage in basic research, small scale process development, scale-up, industrial technology development & production and cost control.
Recommended supplier
-
VIP1年
- SETV ASRV LLP
- EZETIMIBE 95-99 %
- Inquiry
- 2024-09-11
-
VIP1年
- AKASH PHARMA EXPORTS
- Ezetimibe 99%
- Inquiry
- 2024-05-16
-
VIP1年
- Molsyns Research
- Ezetimib Reference Standard 98%
- Inquiry
- 2024-04-01
-
VIP1年
- Aspen Biopharma Labs Pvt Ltd
- Ezetimibe 163222-33-1 98%
- Inquiry
- 2024-03-16
-
VIP1年
- Ratnagene lifescience Pvt Ltd
- Ezetimibe 98%
- Inquiry
- 2024-03-16
-
VIP1年
- Mylan Laboratories Ltd
- 163222-33-1 Ezetimibe 98%
- Inquiry
- 2024-03-06
-
VIP1年
- Bondbay Pharmaceuticals Pvt Ltd
- Ezetimibe 163222-33-1 98%
- Inquiry
- 2024-03-05
-
VIP1年
- Vishrudh laboratories pvt ltd
- 163222-33-1 98%
- Inquiry
- 2024-03-01
-
VIP1年
- Ind Swift Laboratories Ltd
- Ezetimibe 163222-33-1 99%
- Inquiry
- 2024-02-24
-
VIP1年
- BDR Pharmaceuticals International Pvt Ltd
- Ezetimibe 98%
- Inquiry
- 2024-02-24
- Since:2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY